Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
SystImmune Inc.
SystImmune Inc.
Kestrel Therapeutics, Inc.
Washington University School of Medicine
Zumutor Biologics Inc.
Sotio Biotech Inc.
SystImmune Inc.
I-Mab Biopharma US Limited
Myeloid Therapeutics
SEED Therapeutics, Inc.
AbbVie
Henry Ford Health System
University of Nebraska
NextCure, Inc.
University of Maryland, Baltimore
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Fujifilm Pharmaceuticals U.S.A., Inc.
Black Diamond Therapeutics, Inc.
Redx Pharma Ltd
Carisma Therapeutics Inc
Hoffmann-La Roche
Vincerx Pharma, Inc.
Taiho Pharmaceutical Co., Ltd.
Eli Lilly and Company
GeneQuantum Healthcare (Suzhou) Co., Ltd.
The Christie NHS Foundation Trust
Silverback Therapeutics
University of Cincinnati
National Health Research Institutes, Taiwan
Lee's Pharmaceutical Limited
AbGenomics B.V Taiwan Branch
AstraZeneca
Array BioPharma
Masonic Cancer Center, University of Minnesota
AstraZeneca
Johannes Gutenberg University Mainz
ASLAN Pharmaceuticals
Jules Bordet Institute
Kansai Hepatobiliary Oncology Group
GlaxoSmithKline
Kansai Hepatobiliary Oncology Group
University College, London
AstraZeneca
University of California, San Francisco
Kansai Hepatobiliary Oncology Group
University of Colorado, Denver
University of California, San Francisco
Mannkind Corporation